ADVERTISEMENT
Log in here to read the desired article.
ADVERTISEMENT
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 2212 entries already.
The technological and pharmacological advances lead to an increase in the number of molecules for R&D that are challenging and difficult to manufacture. To improve clinical success, pharma and biotech companies are seeking innovative ways to accelerate progress and reduce scientific, economic, and delivery risks.
Quinten Group’s French healthcare arm Quinten Health has closed a financing round to advance disease modeling platforms and virtual twins in real-world.
Bavarian Nordic A/S has expand its smallpox contract signed with the Canadian PHAC in June from $56m to $470m including $180m in contract options.
Why are so many vaccine developers choosing Thermo Scientific Charged Aerosol Detection (CAD)? Hear the third very good reasons why CAD was used for analysis of lipid nanoparticles in approved mRNA vaccines.
Through the acquisition of Versantis for €40m upfront and further €65m in milestones, Genfit SA has added three clinical and preclinical candidates to its liver drug portfolio.
Foodtech startup Standing Ovation SA has closed an oversubscribed €12m Series A financing round led by Astanor Ventures.
HeartBeat.bio and Molecular Devices announce collaboration to automate and scale cardiac organoids for high-throughput drug discovery screening
Dutch researchers report they could detect a COVID-19 infection with better sensitivity than antigen tests by a mobile app that uses AI to analyse voice recordings.
Dutch Pleco Therapeutics BV has raised €17.3m in a Series A financing to push its lead candidate in acute myeloid leukaemia to market approval.
Synaffix B.V. and Emergence Therapeutics AG have entered into a licensing agreement of up to $360m to find ADCs directed against target molecules from Emergence.